In-Hospital Mortality-Associated Factors of Thrombotic Antiphospholipid Syndrome Patients Requiring Intensive Care Unit Admission.
The antiphospholipid syndrome (APS) is a systemic autoimmune disease defined by thrombotic events that can require ICU admission because of organ dysfunction related to macrovascular and/or microvascular thrombosis. Critically ill thrombotic APS patients were studied to gain insight into their prognoses and in-hospital mortality-associated factors. This French national, multicenter, retrospective study included all APS patients with any new thrombotic manifestation(s) admitted to 24 ICUs (January 2000-September 2018). During the study period, 134 patients (male/female ratio, 0.4) with 152 APS episodes were admitted to the ICU (at mean age 46.0 ± 15.1 years). In-hospital mortality of their 134 last episodes was 35/134 (26.1%). The Cox multivariable model retained (HR [95% CI]): age ≥40 years (11.4 [3.1-41.5]; P < .0001), mechanical ventilation (11.0 [3.3-37]; P < .0001), renal replacement therapy (2.9 [1.3-6.3]; P = .007) and in-ICU anticoagulation (0.1 [0.03-0.3]; P < .0001) as independently associated with in-hospital mortality. For the subgroup of "definite/probable CAPS", the Cox bivariable model including the SAPS II score retained double therapy (corticosteroids + anticoagulant: 0.2 [0.07-0.6]; P = .005) but not triple therapy (corticosteroids + anticoagulant + intravenous immunoglobulins or plasmapheresis: HR 0.3 [0.1-1.1]; P = .07) as independently associated with in-hospital mortality. In-ICU anticoagulation was the only APS-specific treatment independently associated with survival for all patients. Double therapy was independently associated with better survival of "definite/probable CAPS" patients. In these patients, further studies are needed to determine the role of triple therapy.